EI
PGNX

EAM Investors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

EAM Investors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-77,912
Closed -$735K – 396
2017
Q1 		$735K Buy
+77,912
New +$778K 0.12% 236
2016
Q4 		– Sell
-144,902
Closed -$917K – 400
2016
Q3 		$917K Buy
+144,902
New +$876K 0.12% 263
2015
Q4 		– Sell
-441,561
Closed -$2.53M – 375
2015
Q3 		$2.53M Sell
441,561
-229,770
-34% -$1.76M 0.4% 99
2015
Q2 		$5.01M Buy
671,331
+155,042
+30% +$938K 0.59% 26
2015
Q1 		$3.09M Sell
516,289
-37,020
-7% -$233K 0.36% 148
2014
Q4 		$4.18M Buy
+553,309
New +$3.31M 0.58% 21

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

EAM Investors's PGNX Position: Q2 2017 in Review

EAM Investors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2017, closing a stake of 77,912 shares — an estimated $735K sold.

EAM Investors first reported a position in PGNX in Q4 2014 and held it in 6 quarters. The position peaked at $5.01M in Q2 2015. 152 funds tracked by Wall St. Rank hold PGNX as of Q2 2017.

  • EAM Investors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • EAM Investors sold 77,912 Progenics Pharmaceuticals Inc shares in Q2 2017, an estimated $735K.
  • EAM Investors first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 6 quarters.
  • EAM Investors's Progenics Pharmaceuticals Inc position peaked at $5.01M in Q2 2015.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2017.

Based on EAM Investors's 13F filing for Q2 2017, filed 11 Aug 2017.